102 results about "Macula lutea degeneration" patented technology

The invention relates to compositions and methods for preventing or treating a macular degeneration-related disorder, comprising a scyllo-inositol compound or pharmaceutically acceptable salts thereof.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, oneor more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

The present invention provides an effervescent dietary supplement formulation that may be beneficial to the management of symptoms related to ocular diseases. Also provided are methods of treating an ocular disease, such as macular degeneration, by administering the dietary supplement to a subject in need thereof.

The invention relates to a preparation method of a zeaxanthin dipalmitate extract in Chinese wolfberry and an application of the zeaxanthin dipalmitate extract in medicinal health-care products. Zeaxanthine can delay ageing, prevent cancers and treat age-related macular degeneration (ARMD or AMD), and is an ideal medicament for preventing and treating diseases caused by free radicals. The Chinese wolfberry is rich in zeaxanthin dipalmitate. According to the method disclosed by the invention, the zeaxanthin dipalmitate extract is extracted from the Chinese wolfberry by using a solvent, and the content of the extract is 1-100 percent; an oral liquid preparation prepared from the zeaxanthin dipalmitate extract is used for preventing cataract and delaying and treating age-related macular degeneration.

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.

The present invention relates to the use of blood vessel target agent, especially tubulin binding agent, to treat diseases such as eye angiogenesis, eye tumor, diabetic retinopathy, premature retinopathy, retinoblastoma and macular degeneration.

The invention relates to a diphenyldihydroporphin compound, a preparation method and application thereof. The compound has the following structure (I) which is shown in the description, wherein R1 andR2 are positioned at the ortho-position (o-), meta-position (m-) or para-position (p-) of a benzene ring; R1 is -H or -OMe; R2 is -OCH2COOH or -OCH2CH2CH2COOH. The invention relates to the fields ofphotosensitive drugs (also called as a photosensitizer or photodynamic drug) and photodynamic therapy, and particularly relates to a diphenyldihydroporphin photosensitizer, a preparation method and application in the field of medicines. The diphenyldihydroporphin compound prepared by the method provided by the invention is stable in chemical property, has strong photodynamic activity, and can be used as a drug for photodynamic diagnosis and treatment of diseases such as tumors, macula-retinae degeneration, actinic keratosis, nevus flammeus and condyloma acuminata and the like.

The invention discloses an application of D609 in preparation of a medicine for preventing and treating retinal injury diseases. The Chinese name of D609 is tricyclic decane-9-yl-dithiocarbonate potassium salt, and the D609 is an antiviral and antitumor small molecular compound, which belongs to a selective inhibitor of phosphatidylcholine specific phospholipase (PC-PLC). According to the invention, the wide and deep research is carried out, the unexpected discovery is realized for the first time, the expression of metallothionein is up-regulated by the D609; the oxidative damage of RPE cellscan be effectively inhibited; therefore, the compound can be used for preventing or treating retinal injury diseases caused by oxidative stress injury of retinal pigment epithelial cells, especially,the compound can be extremely effectively used for preventing or treating macular degeneration diseases of retina, has no obvious drug toxicity, can effectively control the occurrence and developmentof injury diseases of retina, and provides a new theoretical support for developing unknown biological activity of D609 and future clinical treatment effects.

The invention relates to an application of chloroxine in preparing anti-angiogenesis medicine. Until now no relevant reports about the anti-angiogenesis activity of the chloroxine are available. The invention provides the application of chloroxine in preparing anti-angiogenesis medicines, anti-tumor medicines and medicines for preventing wet age-related macular degeneration. The in-vivo pharmacodynamic experiment using a zebra fish angiogenesis model shows that the chloroxine can remarkably suppress zebra fish angiogenesis, remarkably suppress the growth of transplanted human tumor cells and has a therapeutic effect to wet age-related macular degeneration. Therefore, the chloroxine can be used for preparing anti-angiogenesis medicines, anti-tumor medicines and medicines for preventing wet age-related macular degeneration.

Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula where R1 and R2 are, independently, H or C1 to C3 alkyl ; R3 and R4 are, independently C1 to C3 alkyl; and where R1 and R2, taken together, or R3 and R4, taken together, or both may be cycloalkyl; R5 is H, OH, or C1 to C6 alkyl ; R6 is or C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl ; R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R6 and R7, or R5, R6 and R7, taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

The present invention relates to the novel human retina-specific proteins called C7orf9, C12orf7, MPP4 and F379, and isolated nucleic acid molecules encoding said proteins. Also provided are vectors, host cells, antibodies and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating macular degeneration, e.g. AMD.

The invention discloses a doxorubicin structure-containing star-shaped polymer and a preparation method and use thereof. The doxorubicin coupled star-shaped polymer has a better effect on treatment of age-related macular degeneration compared with drugs or medicaments in other forms.

The invention provides a heterocyclic compound containing piperidine as shown in a formula (I). The compounds are used for treating diseases and diseases related to complement alternative pathway activation, such as paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN) including C3 glomerulopathy (C3G), membranous nephropathy (MN) and other glomerular diseases, atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), diabetic retinopathy (DR), and other diseases associated with abnormal activation of the alternative complement pathway by inhibiting/regulating a complement factor B.

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

The invention relates to a novel porphin diether salt compound (I) as well as a preparation method and application thereof. The compound (namely, porphin diether disodium salt, porphin diether dimethyl salt, porphin diether dilithio salt and porphin diether diammonium salt compound) has a structure shown in the description. The compound provided by the invention has the advantages of single component, stable property, controllable quality, simple and convenient preparation method and high water solubility, and can be easily prepared into an injection or a freeze-drying preparation. The compound has remarkable photodynamic activity, and can be applied to photodynamic therapy of tumors, retina macular degeneration, actinic keratosis, nevus flammeus, verruca acuminate and the like.